Biomarker Research

Article	Citations
Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective study	172
Identification of GRIN2D as a novel therapeutic target in pancreatic ductal adenocarcinoma	149
Development and validation of predictive models combining cell-Free DNA motifs and protein biomarkers for early detection of esophageal squamous cell carcinoma and precancerous lesion	138
CardioAtlas: deciphering the single-cell transcriptome landscape in cardiovascular tissues and diseases	137
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes	116
The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma	114
The spatial impact of a Western diet in enriching Galectin-1-regulated Rho, ECM, and SASP signaling in a novel MASH-HCC mouse model	113
Mitochondrial transfer in hematological malignancies	112
Targeting novel regulated cell death: disulfidptosis in cancer immunotherapy with immune checkpoint inhibitors	107
Circulating Tumor DNA from Ascites as an alternative to tumor sampling for genomic profiling in ovarian cancer patients	104
Exosomal PSM-E inhibits macrophage M2 polarization to suppress prostate cancer metastasis through the RACK1 signaling axis	101
Emerging therapeutic agents in multiple myeloma: highlights from the 2024 ASH annual meeting	98
Skin-permeable gold nanoparticles with modifications azelamide monoethanolamine ameliorate inflammatory skin diseases	95
Extracellular vesicle-based liquid biopsy biomarkers and their application in precision immuno-oncology	94
Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancer	94
The overlooked trio: sleep duration, sampling time and physical exercise alter levels of olink-assessed blood biomarkers of cardiovascular risk	84
tRNA modifications in cancer: from molecular mechanisms to clinical translation	83
The molecular landscape of the C1498 murine acute myeloid leukemia cell line	82
A machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphoma	82
Dynamic changes of bone microarchitecture and volumetric mineral density assessed by HR-pQCT in patients with cervical cancer after concurrent chemoradiotherapy: a prospective study	81
Therapeutic targeting of PFKFB3 and PFKFB4 in multiple myeloma cells under hypoxic conditions	81
miR-22-Galectin-1 as an integral signaling axis in regulating metabolism and immunity in HCC	80
Multi-omics profiling reveals intrathymic triggers and novel biomarkers in thymoma-associated myasthenia gravis	79
Emerging roles of circular RNAs and enhancer RNAs: new insights into the development and management of neurodegenerative disorders	78
From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy	78

Monocyte-macrophages modulate intestinal homeostasis in inflammatory bowel disease	74
Metallothionein-3 is a multifunctional driver that modulates the development of sorafenib-resistant phenotype in hepatocellular carcinoma cells	74
mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends	70
Unveiling the potential of CLL-1: a promising target for AML therapy	69
p53 biology and reactivation for improved therapy in MDS and AML	68
Copper homeostasis and copper-induced cell death in tumor immunity: implications for therapeutic strategies in cancer immunotherapy	64
Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer	64
Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients	63
Identification of urinary bacterial genes as biomarkers for non-invasive diagnosis of renal lupus	62
The role and metabolic adaptations of neutrophils in premetastatic niches	61
Correction: Manipulation of cancer cell pyroptosis for therapeutic approaches: challenges and opportunities	61
STAT3–mediated up-regulation of DAB2 via SRC-YAP1 signaling axis promotes Helicobacter pylori-driven gastric tumorigenesis	56
Multiple regulatory events contribute to a widespread circular RNA downregulation in precancer and early stage of colorectal cancer development	54
Nanoparticles-enhanced CAR-T cell therapy: current advances and future directions	53
RUNX1 promotes angiogenesis in colorectal cancer by regulating the crosstalk between tumor cells and tumor associated macrophages	53
The role of BATF in immune cell differentiation and autoimmune diseases	53
Dysregulation of plasma circulating microRNAs in all-cause and cause-specific cancers: the Rotterdam Study	53
Proteomic and histopathologic profiling reveal molecular features and clinical biomarkers of coronary atherosclerosis	52
Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics	52
The methyltransferase-like proteins as core regulators of nucleic acid modifications and post-translation modification of proteins in disease pathogenesis and therapeutic implications	48
Oncogenic ACSM6 impairs CD8+ T cell-based immune response in bladder cancer	48
The involvement of krüppel-like transcription factor 2 in megakaryocytic differentiation induction by phorbol 12-myrestrat 13-acetate	48
Correction: Long non-coding RNA SLC25A21-AS1 inhibits the development of epithelial ovarian cancer by specifically inducing PTBP3 degradation	47
Glycochenodeoxycholic acid promotes hepatocarcinogenesis by inducing hepatic progenitor cell differentiation into cancer-associated fibroblasts via sphingosine-1-phosphate receptor 2 signalling	47
Development of a bispecific antibody that inhibits EGFR and B7H3 in NSCLC	47
Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma	47
Immunophenotypic analysis on circulating T cells for early diagnosis of lung cancer	47
BRD4: an effective target for organ fibrosis	45
Transcriptomic analysis of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals distinct subgroups and precision therapy opportunities	45
Whole genome and RNA sequencing analyses for 254 Taiwanese hepatocellular carcinomas	45
Long-term kinetics of proviral load in HTLV-1 carriers: defining risk for the development of adult T-cell leukemia/lymphoma	43
Isolation and typing techniques for circulating tumor cells	42
Disulfidptosis decoded: a journey through cell death mysteries, regulatory networks, disease paradigms and future directions	41
Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy	41
Correction: Pharmacokinetics of post-transplant cyclophosphamide and its associations with clinical outcomes in pediatric haploidentical hematopoietic stem cell transplantation	40
Correction: Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential	40
The essential roles of FXR in diet and age influenced metabolic changes and liver disease development: a multi-omics study	39
Current advances and future perspectives on the functional roles and clinical implications of circular RNAs in esophageal squamous cell carcinoma: more influential than expected	39
Advances in measurable residual disease assessment for acute myeloid leukemia: from cytogenetics and molecular biology to assessment of the methylation pattern and surface-enhanced Raman scattering as	39
Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis	39
Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis	38
Comparison of proton therapy and photon therapy for early-stage non-small cell lung cancer: a meta-analysis	38
Mega-scale single-cell profiling reveals novel biomarkers associated with acute GvHD after allogeneic hematopoietic stem cell transplantation	37
Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential	36
RBM10 modulation of circRNA biogenesis contributes to its tumor suppressor role in lung adenocarcinoma	36
Updates on CAR T cell therapy in multiple myeloma	36
Intratumor microbiome in cancer progression: current developments, challenges and future trends	36
Functions and mechanisms of lncRNA MALAT1 in cancer chemotherapy resistance	36
The cGAS-STING pathway at the crossroads of neuroimmunology: bridging innate immunity to aging and neurodegeneration	36
Immune cells-derived exosomes function as a double-edged sword: role in disease progression and their therapeutic applications	35

Combined TP53 status in tumor-free resection margins and circulating microRNA profiling predicts the risk of locoregional recurrence in head and neck cancer	35
Single-cell sequencing technology in renal cancer: insights into tumor biology and clinical application	35
Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors	35
Histamine N-methyltransferase (HNMT) as a potential auxiliary biomarker for predicting adaptability to anti-HER2 drug treatment in breast cancer patients	35
Fatty acid metabolism shapes immune responses in chronic lymphocytic leukemia	35
Soluble PD-L1 as a novel biomarker predicts poor outcomes and disease progression in de novo myelodysplastic syndromes	35
Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives	35
Targeting serine-glycine-one-carbon metabolism as a vulnerability in cancers	34
Identification of a miRNAs signature as potential biomarker of mesenchymal phenotype in neuroblastoma patients	34
High-throughput LDI MS technology decodes the distinct metabolic landscape of prostate cancer in a large-scale cohort	34
The importance of critically short telomere in myelodysplastic syndrome	34
Adipose-derived stem cell exosomes: mechanisms and therapeutic potentials in wound healing	33
Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer	33
Single-cell RNA sequencing identifies a subtype of FN1 + tumor-associated macrophages associated with glioma recurrence and as a biomarker for immunotherapy	33
Unlocking the power of extracellular vesicles: multi-omics integration for cancer biomarker discovery	33
Analyzing PKC Gamma (+ 19,506 A/G) polymorphism as a promising genetic marker for HCV-induced hepatocellular carcinoma	32
Baseline extracellular vesicle miRNA-30c and autophagic CTCs predict chemoradiotherapy resistance and outcomes in patients with lung cancer	31
MORF4L2 induces immunosuppressive microenvironment and immunotherapy resistance through GRHL2/MORF4L2/H4K12Ac/CSF1 axis in triple-negative breast cancer	31
Targeting cGAS-STING pathway for reprogramming tumor-associated macrophages to enhance anti-tumor immunotherapy	31
Lysine methylation modifications in tumor immunomodulation and immunotherapy: regulatory mechanisms and perspectives	30
A plasma 9-microRNA signature for lung cancer early detection: a multicenter analysis	30
RNA epigenetic modifications as dynamic biomarkers in cancer: from mechanisms to clinical translation	30
Tumor-specific MHC-II guides anthracycline exemption and immunotherapy benefit in breast cancer	30
Imaging biomarkers for clinical applications in neuro-oncology: current status and future perspectives	30
Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma	30
New cell sources for CAR-based immunotherapy	29
Functional heterogeneity of cancer-associated fibroblasts with distinct neoadjuvant immunotherapy plus chemotherapy response in esophageal squamous cell carcinoma	29
Prevalence and clinical significance of Claudin-3 expression in cancer: a tissue microarray study on 14,966 tumor samples	29
Tobacco smoking associates with NF1 mutations exacerbating survival outcomes in gliomas	29
NLRP4 unlocks an NK/macrophages-centered ecosystem to suppress non-small cell lung cancer	29
Targeting RPS6KC1 to overcome enzalutamide resistance in prostate cancer	28
Targeted protein degradation in hematologic malignancies: clinical progression towards novel therapeutics	28
Plasma proteomics uncovers divergent molecular signatures in ischemic stroke and intracerebral hemorrhage	28
FGL1 and FGL2: emerging regulators of liver health and disease	28
Extracellular matrix: unlocking new avenues in cancer treatment	27
Nanobody-enhanced chimeric antigen receptor T-cell therapy: overcoming barriers in solid tumors with VHH and VNAR-based constructs	27
METTL3 facilitates immunosurveillance by inhibiting YTHDF2-mediated NLRC5 mRNA degradation in endometrial cancer	27
Association between circulating ECM-associated molecules and cardiovascular outcomes in hemodialysis patients: a multicenter prospective cohort study	27
S100A9 as a potential novel target for experimental autoimmune cystitis and interstitial cystitis/bladder pain syndrome	27
HDAC7 induction combined with standard-of-care chemotherapy provides a therapeutic advantage in t(4;11) infant B-cell acute lymphoblastic leukemia	27
Bone morphogenetic protein 2 is a new molecular target linked to non-alcoholic fatty liver disease with potential value as non-invasive screening tool	26
Association of CAR-T approval on outcomes in patients with diffuse large B-cell lymphoma at the population level in the United States	26
Challenges and advances for huntingtin detection in cerebrospinal fluid: in support of relative quantification	26
T cells in cancer: mechanistic insights and therapeutic advances	26
EIF4A3-induced Circ_0001187 facilitates AML suppression through promoting ubiquitin-proteasomal degradation of METTL3 and decreasing m6A modification level mediated by miR-499a-5p/RNF113A pathway	26
Correction: CRISPR/Cas-based CAR-T cells: production and application	25
Epigenetic biomarkers of progestin-resistance in endometriosis	25
USP21-EGFR-Lyn axis drives NSCLC progression and therapeutic potential of USP21 inhibition	25
TUG1: a potential endogenous reference gene for long noncoding RNA quantification in blood-based studies	25
Targeting NOX2 and glycolytic metabolism as a therapeutic strategy in acute myeloid leukaemia	25
Microbiome multi-omics analysis reveals novel biomarkers and mechanisms linked with CD etiopathology	25
Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies	24
Cancer in transition: discovery of tumor-intrinsic transcriptional programs shaping the immune and microenvironmental landscape	24
MiRNAs as potential therapeutic targets and biomarkers for non-traumatic intracerebral hemorrhage	24
Single-cell multi-omics analysis identifies SPP1+ macrophages as key drivers of ferroptosis-mediated fibrosis in ligamentum flavum hypertrophy	24
The multifaceted roles of cathepsins in immune and inflammatory responses: implications for cancer therapy, autoimmune diseases, and infectious diseases	23
High expression of TMEM244 is associated with poor overall survival of patients with T-cell lymphoma	22
A germline FLT3 variant in aplastic anemia	22
Long non-coding RNA PWRN4 associated with post-SVR hepatocellular carcinoma: a genome-wide association study	22
Targeting TIGIT for cancer immunotherapy: recent advances and future directions	22
Immune cell profiling supports early prediction of sepsis-associated acute kidney disease using a decision tree algorithm	21
Cervical cancer heterogeneity: a constant battle against viruses and drugs	21
Crosstalk between lactylation and RNA modifications in tumorigenesis: mechanisms and therapeutic implications	21
Long noncoding RNA LIPH-4 promotes esophageal squamous cell carcinoma progression by regulating the miR-216b/IGF2BP2 axis	21
Piwi-interacting RNA 775 (piR-775) predicts favorable prognosis and regulates cell cycle and DNA damage response pathways in breast cancer	21
MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression	21
The clinical application of ctDNA to predict response to neoadjuvant chemoradiotherapy in patients with locally-advanced rectal cancer	21
Comparing fourteen consensus biomarkers of aging: epigenetic pace of aging as the strongest predictor of mortality in BASE-II	21
THSD4 is a novel mediator of T cell exclusion and anti-PD-1 resistance in hormone receptor-positive breast cancer	21
PCSK9 in T-cell function and the immune response	21
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted	20
Toll-like receptor 3: a double-edged sword	20
The detection, biological function, and liquid biopsy application of extracellular vesicle-associated DNA	20
Harnessing multi-omics approaches to decipher tumor evolution and improve diagnosis and therapy in lung cancer	20
The LILRB family in hematologic malignancies: prognostic associations, mechanistic considerations, and therapeutic implications	20
The significant others of aurora kinase a in cancer: combination is the key	20
PTK2 is a potential biomarker and therapeutic target for EGFR- or TLRs-induced lung cancer progression via the regulation of the cross-talk between EGFR- and TLRs-mediated signals	20
Oncogenic alterations in advanced NSCLC: a molecular super-highway	20
MACC1 revisited – an in-depth review of a master of metastasis	19
Noninvasive biomarkers implicated in urea and TCA cycles for metabolic liver disease	19

Correction: LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/ miR-324-3p-SIRT5 axis in lung adenocarcinoma	19
Identification of exosomal microRNA panel as diagnostic and prognostic biomarker for small cell lung cancer	19
HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma	19
Stratifying high-risk prediabetes clusters using blood-based epigenetic markers	19
Blood and urine biomarkers of disease progression in IgA nephropathy	19
LncRNA AC006064.4–201 serves as a novel molecular marker in alleviating cartilage senescence and protecting against osteoarthritis by destabilizing CDKN1B mRNA via interacting with PTBP1	19
The role of pyroptosis in modulating the tumor immune microenvironment	19
Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects	19
Ribosome profiling: a powerful tool in oncological research	19
The emerging landscape of exosomal CircRNAs in solid cancers and hematological malignancies	19
Deciphering mechanical cues in the microenvironment: from non-malignant settings to tumor progression	19
Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy	19
Comprehensive plasma metabolomics profiling develops diagnostic biomarkers of obstructive hypertrophic cardiomyopathy	18
Exploring non-invasive precision treatment in non-small cell lung cancer patients through deep learning radiomics across imaging features and molecular phenotypes	18
Circulating long non-coding RNAs detection after heart transplantation and its accuracy in the diagnosis of acute cardiac rejection	18
Peripheral blood biomarkers for predicting response to PD-1/PD-L1 inhibitors	18
Targeted protein degradation for fetal hemoglobin induction: a new paradigm in β-hemoglobinopathy therapy	18
Therapeutic landscape of ovarian cancer: recent advances and emerging therapies	18
Phenomic landscape and pharmacogenomic implications for HLA region in a Taiwan Han Chinese population	17
Targeted inhibition of Ninjurin2 promotes chemosensitivity in chemoresistant gastric cancer by suppressing cancer-initiating cells	17
Correction: Deciphering LAG-3: unveiling molecular mechanisms and clinical advancements	17
TRPM channels in human cancers: regulatory mechanism and therapeutic prospects	17
IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia	17
High IL1R1 expression predicts poor survival and benefit from stem cell transplant in intermediate-risk acute myeloid leukemia from the Leucegene cohort	17
Simultaneous inhibition of FAK and ROS1 synergistically repressed triple-negative breast cancer by upregulating p53 signalling	17
Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients	17
Tumor microenvironment and immunotherapy for triple-negative breast cancer	17
Review immune response of targeting CD39 in cancer	17
Antileukemic potential of methylated indolequinone MAC681 through immunogenic necroptosis and PARP1 degradation	16
Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer	16
Leveraging oncovirus-derived antigen against the viral malignancies in adoptive cell therapies	16
Correction: Comprehensive analysis of peroxiredoxins expression profiles and prognostic values in breast cancer	16
Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myeloma	16
Histone modification-regulated LncRNA DLEU1 interacts with ASCC2/ALKBH3 complex to drive DNA repair, antioxidant homeostasis and glucose metabolism in gastric cancer	16
Clinical stabilization of a highly refractory acute myeloid leukaemia under individualized treatment with immune response modifying drugs by in vivo generation of dendritic cells of leukaemic origin (	16
Roles of posttranslational modifications in lipid metabolism and cancer progression	15
Gene therapy for polygenic or complex diseases	15
CAR Macrophages: a promising novel immunotherapy for solid tumors and beyond	15
Revolutionizing oncology: the role of Artificial Intelligence (AI) as an antibody design, and optimization tools	15
Pharmacokinetics of post-transplant cyclophosphamide and its associations with clinical outcomes in pediatric haploidentical hematopoietic stem cell transplantation	15
Circulating tumor DNA for MRD detection in colorectal cancer: recent advances and clinical implications	15
CRISPR/Cas-based CAR-T cells: production and application	15
Detection of circulating tumor cells: opportunities and challenges	15
Exosome derived from tumor-associated macrophages: biogenesis, functions, and therapeutic implications in human cancers	15
Targeting YAP1-CD70 axis potentiates the efficacy of anti-PD-1 therapy in prostate cancer	14
Serum metabolite signatures of cardiac function and morphology in individuals from a population-based cohort	14
Combination immunotherapy targeting LAG-3, PD-1 and STING suppresses hepatocellular carcinoma as monitored by LAG-3 targeted PET imaging	14
Global, regional, and national burden of heart failure and its underlying causes, 1990–2021: results from the global burden of disease study 2021	14
Physio-pathological effects of N6-methyladenosine and its therapeutic implications in leukemia	14
Clinical and structural insights into concurrent EGFR and MET exon 14 skipping mutations in NSCLC: a multi-center series	14
Correction: A novel 3-miRNA network regulates tumour progression in oral squamous cell carcinoma	13
DeepMPTB: a vaginal microbiome-based deep neural network as artificial intelligence strategy for efficient preterm birth prediction	13
Global surveillance of circulating microRNA for diagnostic and prognostic assessment of acute myocardial infarction based on the plasma small RNA sequencing	13
The role of platelets in cancer: from their influence on tumor progression to their potential use in liquid biopsy	13
A functional role of Ephrin type-B receptor 6 (EPHB6) in T-cell acute lymphoblastic leukemia	13
LRG1, a novel serum biomarker for iMCD disease activity	13
Folate receptor 1 is a stemness trait-associated diagnostic and prognostic marker for hepatocellular carcinoma	13
Development and validation of an integrative 54 biomarker-based risk identification model for multi-cancer in 42,666 individuals: a population-based prospective study to guide advanced screening strat	13
Integrative multi-omics analysis depicts the methylome and hydroxymethylome in recurrent bladder cancers and identifies biomarkers for predicting PD-L1 expression	13
The war between the immune system and the tumor - using immune biomarkers as tracers	13
Correction: Vitamin D activates FBP1 to block the Warburg effect and modulate blast metabolism in acute myeloid leukemia	13
Biomarkers as targets for CAR-T/NK cell therapy in AML	13
Deciphering metabolic heterogeneity in retinoblastoma unravels the role of monocarboxylate transporter 1 in tumor progression	13
Global burden of breast cancer and attributable risk factors in 204 countries and territories, from 1990 to 2021: results from the Global Burden of Disease Study 2021	13
Untargeted lipidomics reveals racial differences in lipid species among women	13
Current challenges and best practices for cell-free long RNA biomarker discovery	12
The role of biomarkers in personalized immunotherapy	12
Integrating artificial intelligence in drug discovery and early drug development: a transformative approach	12
Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients	12
Heat shock proteins (HSPs) in non-alcoholic fatty liver disease (NAFLD): from molecular mechanisms to therapeutic avenues	12
Competing endogenous RNA networks related to prognosis in chronic lymphocytic leukemia: comprehensive analyses and construction of a novel risk score model	12
Prognostic and predictive biomarkers for response to neoadjuvant chemoradiation in esophageal adenocarcinoma	12
Advances of cancer-associated fibroblasts in liver cancer	12
Single cell spatial profiling of FFPE splenic tissue from a humanized mouse model of HIV infection	12
Characterization of T-Cell receptor repertoire in immunoglobulin a nephropathy	12
Soluble immune checkpoint molecules in cancer risk, outcomes prediction, and therapeutic applications	12
Phenotypic and metabolomic characteristics of mouse models of metabolic associated steatohepatitis	12
The application of Aptamer in biomarker discovery	12
Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML	12
Effect of regulatory cell death on the occurrence and development of head and neck squamous cell carcinoma	12
Advancement in Multi-omics approaches for Uterine Sarcoma	12
Bioinformatics tools and data resources for assay development of fluid protein biomarkers	12
Deciphering the correlation between metabolic activity through 18F-FDG-PET/CT and immune landscape in soft-tissue sarcomas: an insight from the NEOSARCOMICS study	12
Multi-omics biomarkers in female fertility: from oocyte quality to endometrial receptivity and clinical translation	12
Machine learning-based radiomics model: prognostic prediction and mechanism exploration in patients with endometrial cancer	11
Targeting myeloid cells for hematological malignancies: the present and future	11
The impact of integrated hepatitis B virus DNA on oncogenesis and antiviral therapy	11
Molecular network of metabolic reprogramming and precision diagnosis and treatment of hepatocellular carcinoma	11
Harnessing natural killer cells for refractory/relapsed non-Hodgkin lymphoma: biological roles, clinical trials, and future prospective	11
The landscape overview of CD47-based immunotherapy for hematological malignancies	11
Lactate and lactylation: molecular insights into histone and non-histone lactylation in tumor progression, tumor immune microenvironment, and therapeutic strategies	11
Comparative analysis of microRNA expression in serum and plasma in patients screened for BRCA1 or BRCA2 mutations	11
Microfluidic biosensors for biomarker detection in body fluids: a key approach for early cancer diagnosis	11
Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases	10
METTL1 promotes neuroblastoma development through m7G tRNA modification and selective oncogenic gene translation	10